IRVINE, Calif. (PRWEB) January 28, 2015
Nurotron Biotechnology Co., Ltd., has received approval from India’s Central Drugs Standard Control Organization (CDSCO).
Nurotron, which designs, develops and markets neural-electronic medical devices and systems, received approval from CDSCO to sell its Venus Cochlear Implant System in India. The system is a safe, reliable and effective solution for children and adults suffering from severe and profound hearing loss.
Headquartered in New Delhi, CDSCO is India's main regulatory body for pharmaceuticals and medical devices. CDSCO organization safeguards and enhances the public health by assuring the safety, efficacy and quality of drugs, cosmetics and medical devices.
"This approval by India's primary drug and medical device oversight organization is a major achievement for Nurotron’s cochlear implant system," says Chu Li, CEO of Nurotron. "The validation of the efficacy of Nurortron’s offerings in the important Indian market confirms the company’s position as a global leader in cochlear implant technology.” Nurotron already holds the CE mark in Europe for the Venus Cochlear Implant System, and has received approval to sell in China and Turkey as well.
Nurotron Biotechnology Co., Ltd. (http://en.nurotron.com)
Nurotron Biotechnology is a medical device company that designs, develops and markets neural-electronic medical devices and systems. The company’s flagship system is the Venus Cochlear Implant System, a safe, reliable and effective solution for children and adults suffering from severe and profound hearing loss.
The global leader in cochlear implant technology maintains its research and development center in Irvine, Calif., and manufacturing facilities in China. Founded in 2006, Nurotron is headquartered in Hangzhou, China.